Short Interest in CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) Decreases By 49.6%

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) was the target of a significant decline in short interest in May. As of May 29th, there was short interest totaling 42,484 shares, a decline of 49.6% from the May 14th total of 84,316 shares. Based on an average daily trading volume, of 38,729 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.3% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised CollPlant Biotechnologies from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $11.50.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CollPlant Biotechnologies stock. Villere ST Denis J & Co. LLC increased its stake in shares of CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) by 3.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 607,300 shares of the company’s stock after purchasing an additional 18,583 shares during the quarter. Villere ST Denis J & Co. LLC owned 4.75% of CollPlant Biotechnologies worth $850,000 at the end of the most recent quarter. Institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Price Performance

CLGN opened at $0.34 on Friday. CollPlant Biotechnologies has a 12 month low of $0.27 and a 12 month high of $3.23. The stock has a market capitalization of $4.89 million, a price-to-earnings ratio of -0.23 and a beta of 1.57. The business has a fifty day moving average price of $0.39 and a 200 day moving average price of $0.95.

CollPlant Biotechnologies (NASDAQ:CLGN) last released its earnings results on Friday, May 29th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. CollPlant Biotechnologies had a negative return on equity of 218.81% and a negative net margin of 683.68%.The firm had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.46 million.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.